NCT01660607View on ClinicalTrials.gov

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 9, 2012

Primary Completion Date

December 20, 2023

Study Completion Date

December 20, 2023

Conditions
Myeloid Leukemia, ChronicAcute Myelogenous LeukemiaMyelodysplastic Syndromes (MDS)Lymphoma, Non-HodgkinAcute Lymphoblastic Leukemia (ALL)Myeloproliferative SyndromeAcute Myeloid LeukemiaAcute LeukemiaChronic Myelogenous Leukemia
Interventions
BIOLOGICAL

CD34+ Hematopoietic Progenitor Cells (HSPC)

Purified CD34+ hematopoietic progenitor cells used in transplantation.

BIOLOGICAL

Regulatory T-Cells (Treg)

Highly purified CD4+CD25+CD127-FoxP3+ regulatory T cells to reduce graft-versus-host disease.

BIOLOGICAL

Conventional T-Cells (Tcon)

Conventional CD3+ T cells used for immune reconstitution and graft enhancement.

PROCEDURE

Myeloablative Conditioning Regimen

Chemotherapy or total body irradiation used before hematopoietic cell transplantation.

Trial Locations (1)

94305

Stanford University School of Medicine Palo Alto, California, United States, Palo Alto

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Stanford University

OTHER

NCT01660607 - Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | Biotech Hunter | Biotech Hunter